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Abstract Previous evidence has shown that the majority of the
interferon-inducible, double-stranded RNA-dependent protein
kinase PKR is associated with ribosomes in vivo. Here we show
that ribosomes are inhibitory for PKR activity since they
compete with dsRNA for binding to PKR, inhibit the activation
of the protein kinase by dsRNA, and prevent the phosphorylation
of the PKR substrate eIF2K. We suggest that ribosomes
constitute a reservoir of inactive PKR and that the protein
kinase must be displaced from the ribosome by dsRNA in order
to become activated.
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1. Introduction
The interferon-inducible, double-stranded RNA (dsRNA)-
dependent protein kinase PKR is an important factor for the
regulation of protein synthesis in response to viral infections
and following exposure of uninfected cells to a variety of
physiological stresses [1,2]. In both animal and plant systems
PKR is activated by viral dsRNA or by stem-loop structures
in mRNAs [3^5] in a process which involves dimerisation and
autophosphorylation of the enzyme (reviewed in [6]). In in-
fected cells PKR plays an important role in the antiviral ef-
fects of the interferons by inhibiting protein synthesis due to
the phosphorylation of the K subunit of polypeptide chain
initiation factor eIF2 [1]. In uninfected cells PKR is activated
by stress conditions such as high cell density, growth factor
deprivation or mobilisation of calcium by the ionophore
A23187 [7^9]. The kinase is also involved in the regulation
of cell growth. The wild-type form inhibits cell proliferation,
whereas inactive mutant forms can transform cells to a tu-
morigenic phenotype [10^12]. Several mutants have a domi-
nant negative e¡ect on the wild-type enzyme in mammalian
cells and in transfected yeast strains [13], as well as in vitro
[14,15]. Other studies have shown that additional inhibitors of
PKR activity, such as the protein p58IPK and the cellular TAR
binding protein, also transform cells when these proteins are
over-expressed [16,17].
PKR is a relatively abundant protein, at least in some cell
types. We have previously estimated that it is present in hu-
man Daudi cells at a level approximately equal to 20% of that
of ribosomes [18]. After interferon treatment this increases to
a concentration that is roughly equimolar with ribosomes.
Moreover, cellular fractionation studies indicate that the ma-
jority of the protein kinase is associated with ribosomes in the
cell, at least prior to interferon treatment [18]. Zhu et al. [19]
have shown that, in a yeast expression system, PKR binds to
40S ribosomal subunits independently of mRNA and have
produced evidence, based on mutagenesis studies, that the
dsRNA binding motifs in the N-terminal part of the protein
are required for the ability of the protein to bind to ribo-
somes. In view of this data it is possible that the ribosome
itself plays a role in the regulation of PKR activation or
activity, but no previous studies have addressed this question.
Here we have investigated the strength of binding of PKR to
ribosomes, the ability of ribosomes to in£uence PKR-dsRNA
interactions, and the e¡ect of ribosomes on the protein kinase
activity of PKR in vitro.
2. Materials and methods
2.1. Materials
The synthetic dsRNA poly(I)Wpoly(C) was purchased from Sigma
and dissolved in 50 mM KCl. [Q-32P]ATP was obtained from ICN
Biomedical and ECL kits for immunoblotting were purchased from
Amersham. A monoclonal antibody speci¢c for human PKR (MAb
71/10) [20] was a kind gift from Drs A. Hovanessian and E. Meurs
(Paris).
2.2. Preparation of ribosomes
Ribosomes were prepared from HeLa cells by lysing the cells in low
salt bu¡er (20 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2,
1 mM DTT) containing protease inhibitors (1 mM PMSF, 1 WM
pepstatin A and 1 WM leupeptin). The lysates were centrifuged at
30 000Ug for 20 min followed by 504 000Ug for 70 min. The pelleted
ribosomes from the latter centrifugation were resuspended in RB bu¡-
er (10 mM Tris-HCl, pH 7.5, 80 mM KCl, 1.5 mM MgCl2). These
conditions retain associated proteins on the ribosomes. Alternatively,
ribosomes were resuspended in 10 mM Tris-HCl, pH 7.5, 900 mM
KCl, 5 mM MgCl2 to remove all ribosome-associated proteins, cen-
trifuged through a cushion of 0.5 M sucrose in the same bu¡er and
resuspended in RB bu¡er. The salt-washed ribosomes were stored in
aliquots at 370‡C.
2.3. Preparation of PKR
Enzymatically active wild-type PKR was prepared from rabbit liver
ribosomal salt wash by chromatography on DEAE-cellulose and
FPLC Mono-S columns as described previously [21]. The PKR thus
obtained was dependent on dsRNA for activation and was free of
other detectable protein kinase activities. A PKR point mutant
(K296R) was also puri¢ed from insect cells infected with a recombi-
nant baculovirus (a gift from Dr M. Katze, University of Washing-
ton) [14]. This form of the enzyme has no protein kinase activity but
retains normal RNA binding properties [22].
2.4. Immunoblotting
The amount of PKR associated with ribosomes was determined by
centrifugation of incubations at 436 000Ug for 60 min at 4‡C, fol-
lowed by resuspension of the pellets in SDS gel sample bu¡er. Gel
electrophoresis and immunoblotting were performed as described pre-
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viously [18], using the monoclonal antibody against human PKR.
Detection was by enhanced chemiluminescence using a horseradish
peroxidase-linked secondary antibody and an ECL kit (Amersham).
2.5. Preparation of labelled dsRNA
A radioactive 940 bp dsRNA species was prepared by in vitro sym-
metrical transcription of exon 2 of the mouse c-myc gene using T7 and
SP6 RNA polymerases for synthesis of the two respective strands, as
described previously [23]. The strand transcribed by T7 polymerase
was radioactively labelled by inclusion of [K-32P]UTP in the transcrip-
tion mix. The two strands were annealed to produce the radioactive
dsRNA, which had a speci¢c radioactivity of 1.5U105 cpm/Wg.
2.6. Filter binding assays
Formation of complexes between PKR and dsRNA was assessed by
retention of radioactivity in 32P-labelled c-myc dsRNA on cellulose
nitrate ¢lters. The labelled RNA was incubated with PKR in 25 Wl
reaction volumes for 15 min at 30‡C in the presence of 10 mM Tris-
HCl, pH 7.5, 75 mM KCl, 0.8 mM Mg acetate and 200 Wg/ml bovine
serum albumin. To terminate the reactions, samples were added to
100 Wl of wash bu¡er (containing the same ionic components as the
incubation mix) and were immediately ¢ltered under gentle suction.
The ¢lters were washed with 4U200 Wl of wash bu¡er, dried and the
radioactivity counted in a scintillation counter.
2.7. Phosphorylation assays and phosphorimaging
PKR activity was determined by an autophosphorylation assay as
described previously [23,24]. Puri¢ed wild-type kinase (from rabbit
liver) was incubated with [Q-32P]ATP (10 WCi), in the presence or
absence of the poly(I)Wpoly(C) activator (0.1 Wg/ml), in autophos-
phorylation bu¡er (10 mM Tris-HCl, pH 7.5, 100 mM KCl, 2 mM
MnCl2, 2 mM MgCl2, 0.1 mM EDTA, 10% glycerol). The incubation
volume was 20 Wl. In some experiments 300 ng of puri¢ed recombi-
nant eIF2K [25] (a gift from Dr S. Kimball, University of Pennsylva-
nia) was added as a substrate for PKR. Samples were analysed by
SDS gel electrophoresis followed by autoradiography and phosphor-
imaging.
3. Results
3.1. Binding of PKR to ribosomes
Several previous studies have shown that PKR associates
with ribosomes both in vitro and in intact cells [18,19,26], but
no previous data have been published concerning the salt
sensitivity of this binding. Fig. 1a illustrates that the associa-
tion of PKR with ribosomes from HeLa cells is very stable
since a salt concentration of 400 mM is required to remove
approximately 50% of the protein kinase in vitro. Even at a
KCl concentration of 800 mM the ribosomes are not com-
pletely depleted of endogenous PKR. Similarly, puri¢ed PKR
is still able to reassociate with salt-washed ribosomes in vitro
in the presence of high concentrations of salt, as shown in Fig.
1b.
Since the binding of RNA ligands to PKR is also stable
under high salt conditions [27] strong association of the pro-
tein kinase with ribosomes would be consistent with previous
evidence [19] for an interaction between one or both dsRNA
binding motifs of PKR and a site on the 40S subunit (perhaps
a region of exposed double-stranded 18S ribosomal RNA),
independent of the presence or absence of ribosome-associ-
ated mRNA. In accordance with this suggestion, the synthetic
dsRNA poly(I)Wpoly(C) can at least partially displace PKR
from ribosomes, even under low salt conditions, as shown in
Fig. 2a,b. (Note that the incomplete displacement of PKR by
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Fig. 1. Association of PKR with ribosomes is resistant to high salt concentrations. a: Ribosomes were prepared from HeLa cells and resus-
pended in RB bu¡er, as described in Section 2. Various concentrations of KCl were added to 10 Wg of ribosomes to give the ¢nal values indi-
cated and the ribosomes were incubated on ice for 30 min. Following recovery by centrifugation the ribosomes were resuspended in SDS sam-
ple bu¡er and PKR was detected by SDS gel electrophoresis and immunoblotting. The upper panel shows the autoradiogram of the ECL
assay. Lane C contains 0.6 Wg of puri¢ed recombinant PKR as a positive control. The lower panel shows quantitation of the data by laser den-
sitometry. b: Ribosomes were washed in high salt to remove endogenous PKR and 60 Wg were then incubated with 0.6 Wg of PKR (K296R)
for 15 min at 30‡C in the presence of the concentrations of KCl indicated. The ribosomes were centrifuged through a 0.5 M sucrose cushion
containing the same salt concentrations and then treated as in a. The lane labelled ‘No PKR’ shows the signal obtained with the salt-washed ri-
bosomes alone. Lane C contains 0.25 Wg of puri¢ed recombinant PKR as a positive control.
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poly(I)Wpoly(C) is probably due to the high (non-limiting)
amount of ribosomes required for technical reasons in such
experiments.) Further evidence for competition between ribo-
somes and dsRNA for a common binding site on PKR is seen
when the association of labelled dsRNA with the protein is
measured in a ¢lter binding assay. Fig. 2c shows that salt-
washed ribosomes are able to inhibit the binding of dsRNA
to the kinase in such an assay.
3.2. Regulation of PKR activity by ribosomes
Since ribosomes and dsRNA apparently compete with each
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Fig. 3. Ribosomes inhibit PKR autophosphorylation. Puri¢ed wild-
type PKR (600 ng) was incubated with [Q-32P]ATP in the presence
or absence of dsRNA (0.1 Wg/ml of poly(I)Wpoly(C)) and the various
concentrations of salt-washed ribosomes indicated, under protein
kinase assay conditions (Section 2). After 20 min at 30‡C the reac-
tions were stopped with 2USDS gel sample bu¡er and analysed by
15% polyacrylamide SDS gel electrophoresis and phosphorimaging.
a: Autophosphorylation. PKR, dsRNA and ribosomes were present
as indicated. b: Quantitation of the extent of dsRNA-dependent au-
tophosphorylation of PKR as a function of ribosome concentration,
as determined by phosphorimager analysis. The data are presented
as % of the value obtained with PKR and dsRNA alone.
Fig. 2. a, b: Inhibition by dsRNA of PKR binding to ribosomes.
Salt-washed ribosomes from HeLa cells (20 pmol per 50 Wl reaction)
were incubated with 0.5 Wg of puri¢ed PKR (K296R) at 30‡C for
30 min in 10 mM Tris-HCl (pH 7.5), 75 mM KCl, 1.5 mM MgCl2,
in the presence of 0, 0.1, 1 and 10 Wg/ml of poly(I)Wpoly(C). The ri-
bosomes were then pelleted through a 0.5 ml cushion of 0.5 M su-
crose in the same bu¡er by centrifugation at 436 000Ug for 80 min
at 4‡C, resuspended in SDS sample bu¡er and subjected to electro-
phoresis on a 15% SDS polyacrylamide gel. The gel was probed for
PKR by immunoblotting (a) as described in Section 2. Panel b
shows quantitation of the data by laser densitometry. c: Inhibition
by ribosomes of dsRNA binding to PKR. C-myc dsRNA (105 cpm)
was incubated in the presence or absence of 20 ng of puri¢ed PKR
(K296R) with increasing concentrations of salt-washed ribosomes as
indicated. After 15 min at 30‡C the incubations were analysed for
RNA-protein binding using a ¢lter binding assay (Section 2). b, to-
tal dsRNA bound; a, dsRNA bound to ribosomes in the absence
of PKR; R, dsRNA bound to PKR (by di¡erence).
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other for PKR binding we have examined the functional
e¡ects of salt-washed ribosomes on the activation of the pro-
tein kinase in vitro. Fig. 3 shows that the well-established
requirement for dsRNA for the autophosphorylation of
PKR, which re£ects the activation of the kinase, cannot be
met by ribosomes instead. Moreover, ribosomes very e¡ec-
tively prevent the autophosphorylation of the protein kinase
in the presence of an otherwise optimal concentration of pol-
y(I)Wpoly(C). These data are consistent with the competition
for binding noted above but indicate that only dsRNA can
provide the necessary conditions for autophosphorylation of
PKR.
The best characterised substrate of PKR is the K subunit of
the polypeptide chain initiation factor eIF2, which is itself a
ribosome-associated protein for at least part of its functional
cycle during protein synthesis [28]. We have investigated
whether ribosomes can interfere with the phosphorylation of
eIF2K by PKR which has been preactivated for 20 min in the
presence of dsRNA. Fig. 4 indicates that this is indeed the
case; the addition of increasing amounts of ribosomes
resulted in a substantial drop in the 32P labelling of eIF2K
in vitro.
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Fig. 4. Ribosomes inhibit phosphorylation of eIF2K by PKR. Wild-
type PKR was incubated with poly(I)Wpoly(C) (0.1 Wg/ml) in the ab-
sence of ribosomes under protein kinase assay conditions; after 20
min at 30‡C recombinant eIF2K (300 ng) and the indicated concen-
trations of ribosomes were added and incubation continued for an-
other 10 min. Samples were analysed by SDS gel electrophoresis
and autoradiography (a). b: Quantitation of the extent of eIF2K
phosphorylation as determined by phosphorimaging.
Fig. 5. A model for regulation of PKR by ribosomes before and
after interferon treatment. a: Inactive ribosome-associated PKR. In
the absence of interferon treatment PKR is present at a low level in
the cell, and the majority of it is tightly bound to ribosomes. The
inhibitory e¡ect of the ribosome prevents the kinase from being ac-
tivated by RNA species with minimal secondary structure and only
a relatively weak a⁄nity for PKR. b: Dimerisation and activation
of ribosome-associated PKR. Ribosome-bound PKR can be dis-
placed from the ribosome and activated by dsRNA species which
have extensive secondary structure and a high a⁄nity for PKR.
Such molecules may include both ribosome-associated mRNA spe-
cies (shown) and soluble dsRNA (e.g. viral transcripts) (not shown).
c: Activation of soluble PKR. Following interferon treatment the
level of PKR in the cell increases and a proportion may no longer
be associated with ribosomes. This soluble PKR, in the absence of
the constraining in£uence of the ribosome, may be more readily ac-
tivated by cellular or viral dsRNAs. In all cases activation of PKR
requires homodimerisation (although both molecules in the homo-
dimer may not necessarily need to be in contact with the dsRNA),
followed by autophosphorylation of the protein kinase.
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4. Discussion
A number of physiological roles have been ascribed to PKR
in both uninfected and virus-infected cells. As a result of its
ability to phosphorylate the K subunit of eIF2 PKR is able to
inhibit the guanine nucleotide exchange function of eIF2B and
thereby down-regulate protein synthesis [28]. During virus in-
fections this serves to restrict the ability of the cell to make
new viral proteins, thus protecting the body from the spread
of infection. However, there is growing evidence that inhib-
ition of protein synthesis in uninfected cells by PKR may also
be important as a means of controlling cell growth (reviewed
in [2]) and/or increasing the susceptibility of cells to apoptosis
[29^32]. Clearly, it is important that PKR activity should be
closely regulated under such circumstances. A number of cel-
lular inhibitors of PKR have been described (reviewed in
[2,33]). The best characterised of these is the protein p58IPK
which appears to be part of a complex regulatory pathway for
controlling the activity of the protein kinase during cell stress
[16,34^36]. Our present data suggest that ribosomes them-
selves may also play a signi¢cant role in inhibiting PKR ac-
tivity under normal conditions.
Activation of PKR by dsRNA requires binding of the lig-
and to one or both of the dsRNA binding motifs in the N-
terminal half of the protein. These regions are also required
for the dimerisation of the protein kinase, a necessary step in
its activation by autophosphorylation [13,37]. DsRNA binds
to these motifs with a very high a⁄nity, estimates of the dis-
sociation constant for PKR-dsRNA interactions indicating
values in the nanomolar range [38,39]. Zhu et al. [19] have
shown that the dsRNA binding motifs of PKR are also nec-
essary for association of the kinase with ribosomes in a yeast
model system. Our data, which are consistent with these pre-
vious studies, indicate that the binding of PKR to ribosomes
is at least as strong as that of many initiation factors, 600^800
mM salt being required to prevent binding or to remove the
majority of the kinase from the ribosome. It is likely that
protein-RNA interactions constitute the basis of this stable
association of PKR with the ribosome.
Both the mechanism of binding and the strength with which
it occurs may be physiologically important in preventing in-
appropriate activation of PKR under normal cellular condi-
tions, as illustrated schematically in Fig. 5. For example, the
inhibitory e¡ect of ribosomes might prevent regions of
mRNA with limited secondary structure from activating
PKR spuriously as they are being translated, whilst at the
same time preventing the kinase from becoming soluble in
the cell and thus potentially interacting with other dsRNA
ligands (Fig. 5a). However, it is possible that when larger
amounts of dsRNA accumulate in the cytoplasm (e.g. during
virus infection), or when molecules with a particularly high
a⁄nity for PKR are present, they may compete e¡ectively for
PKR, allowing the latter to become displaced from the ribo-
some and activated (Fig. 5b). An additional element of our
model is that after interferon treatment the amount of PKR
approaches (or may even exceed) the level of ribosomes in the
cell [18]. A proportion of this additional PKR may not be
associated with ribosomes in the cytoplasm and thus might
be more easily activated (Fig. 5c). This would be consistent
with the earlier observations by Langland and Jacobs [40] that
PKR that is not associated with ribosomes after interferon
treatment is dimeric (implying activation) whereas the ribo-
some-bound form of the kinase is both monomeric and less
phosphorylated (and thus probably inactive). The model fur-
ther predicts that virus infection, at least in the absence of
interferon treatment, may lead not only to an increase in the
proportion of PKR that is phosphorylated but also to a re-
duction in the amount of PKR associated with ribosomes.
Although this has not yet been tested in mammalian cells,
both e¡ects have recently been observed in a plant system
infected with tobacco mosaic virus [41].
Our model could account for the evidence that localised
activation of PKR can occur in an mRNA-speci¢c way (e.g.
after some types of virus infection [42] or during the expres-
sion of genes from transiently transfected plasmids [43,44]).
Thus PKR molecules that are initially ribosome-bound may
become displaced and activated by speci¢c mRNAs with ex-
tensive secondary structure, but remain in the vicinity of those
mRNAs (which may still themselves be associated with ribo-
somes). The eIF2K substrate is of course also a ribosome-
associated protein for at least part of its functional cycle dur-
ing protein synthesis [28].
Finally, the question arises as to what prevents PKR acti-
vation while it is bound to ribosomes. There are several prece-
dents for inhibitory RNA molecules that compete with PKR
activators for binding to the same site(s) on the protein kin-
ase, although it is not yet entirely clear what structural fea-
tures distinguish inhibitory RNAs from activating ones. Such
a mechanism is used by the VAI RNA of adenovirus [45,46],
the TAR RNA of HIV-1 [47] and the EBER-1 RNA of Ep-
stein-Barr virus [21] as a means of inhibiting PKR activity. It
is tempting to speculate that these viruses have evolved strat-
egies that mimic an existing host cell control mechanism for
preventing PKR activation, based on the ability of an inhib-
itory cellular rRNA structure to sequester the protein kinase
in an inactive form.
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